Page 84 - Amgen News Today

(Family Features) About 38% of American adults have high cholesterol, which can be caused by poor lifestyle habits or genetics, according to the Centers for Disease Control and Prevention. Having

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient

Hazlett Burt & Watson Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,182 shares of the medical research company’s stock after selling 70 shares during the period. Hazlett Burt […]

Perennial Advisors LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,348 shares of the medical research company’s stock after acquiring an additional 196 shares during the […]

E&G Advisors LP reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 8.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,272 shares of the medical research company’s stock after selling 200 shares during the quarter. E&G […]

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Perennial Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,348 shares of the medical research company’s stock after acquiring an additional 196 shares during the quarter. […]

/PRNewswire/ -- DelveInsights Giant-Cell Arteritis Market Insights report includes a comprehensive understanding of current treatment practices, giant-cell...

Trifecta Capital Advisors LLC increased its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.7% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 8,875 shares of the medical research company’s stock after buying an additional 482 shares during the quarter. Trifecta Capital Advisors LLC’s holdings in […]

E&G Advisors LP lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 8.1% in the fourth quarter, Holdings Channel reports. The firm owned 2,272 shares of the medical research company’s stock after selling 200 shares during the quarter. E&G Advisors LP’s holdings in Amgen were worth $654,000 as of its most […]